DOCSLIB.ORG

Cellular and Humoral Components of Monocyte and Neutrophil Chen1otaxis in Cord Blood

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cellular and Humoral Components of Monocyte and Neutrophil Chen1otaxis in Cord Blood Pediat. Res. 11: 677-()1\0 (1977) Chemotaxis neutrophil complement newborn monocytes phagocytes Cellular and Humoral Components of Monocyte and Neutrophil Chen1otaxis in Cord Blood SAYITA G . PAHWA.""'' RAJENDRA PAHWA. ELENA GRII\IES. AND E LIZA13 ETII SI\IITII\VICK Departlllt'lll of Pediatrics aml/nmrwwlogy, Memorial Sloa/1-1\ellcrillg Ca11ca Centa, Nell' York, New York , USA Summary experiment, blood from a healthy adult was tested simultane­ ously. 1\lonoqte and polymorphonuclear neutrophil (J>I\IN) chemo­ taxis was studied in cord blood from healthv term infants. 1\Jono­ ISOLATION OF CELLS c;yte chemotaxis was normal to increased ( 115-126%) whereas PI\IN chemotaxis was decreased (79%) in comparison with that Mononuclear leukocytes were isolated by density gradient of healthy adult l'ontrol subjects. Generation of chemotactic centrifugation on a sodium mctrizoatc-Ficoll solution (Lympho­ factors from cord sera was impaired, being 55% of that gener­ prep. Nyegard and Co., Oslo) (5). The cells were washed three ated by J)(Wied normal human serum (I'NIIS). Cord serum was times and resuspended in RPI\11 (Gibco) supplemented with less inhibitory than pooled adult human serum fur adult mono­ penicillin 50 units, streptomycin 50 Jlg . and glutamine 2 ml\1/ml. qtes when the cells were suspended in HI % serum and tested for As simultaneous analysis of monocytcs by myelopcroxidasc stain chemotaxis. No inhibition of chemotactic factors by either cord and Wright stain were in close agreement. the percentage of or adult sera was observed. The dissociation of chemotactic monocytcs was routinely determined by a myelopcroxidasc stain response of the two diiTerent phagocytic cells may represent a ( 13 ); Wright stain was done to exclude contamination by gra nu­ protecth·e mechanism whereby one cell can compensate for a locytes. The final cell concentration was adjusted to I .5 x I on defect in the res1lonse of the other. monocytcs/ml. To isolate polymorphonuclear ncutrophils, the granulocyte­ Speculation rich. red blood cell sediment from the Lymphoprep gradient was resuspended in RPM I I ()40 ; the red blood cells were then Simultaneous anal_ysis of monocyte and neutrophil chemotaxis scdimentcd with 6 % dextran in saline solution (Abbott). Rc LI may reveal a defect restricted to one cell type. blood cells remaining in the leukocyte-rich supernatant were lysed with hypotonic saline . The leukocytes were then washed three times and resuspended in minimum essential medium The human newborn infant is uniquely susceptible to infection (MEM , Gibco) at a concentration of 1.0 x 10'; PMN's/ ml. with a variety of infectious agents (bacterial, viral. fungal, and protozoal) which often results in disseminated disease. Many CII Et\tOTACTIC STI1\IULI studies of the defense mechanisms in newborn infants have been done, including studies of cell-mediated and humoral immunity Lymplzocytc-dcril'cd Clzmzolllctic Factor ( LDCF). This lym­ ( 12, II-i), neutrophil function (lJ, 20. 23). inflammatory response phokinc was prepared by concanavalin A (I 0 1-lg/ml) stimulation (R, 10), and the complement system (2, 17). Little information is of lymphocytes. Cultures containing 2 X I on lymphocytcs/ ml in available about the monocyte, a cell of great importance in both RPMI 1640 without serum we re incubated at 37o in 5 % the afferent and efferent limb of the immune response. Evidence SI5 % humiLiificd air for 48 hr. After centrifugation , the superna­ in mice (I), rats (3), anti rabbits (2-1) suggests that the neona te tant Ouid was stored in aliquots at -70° until usctl . LDCF was has a deficiency in macrophage function . In humans, e valuation used as the chemotactic stimulus fur monocytes in the following of the newborn infant's inflammatory response using the Rebuck proportion: 30% LDCF, 40% RPMI 1640, and 30% Hank's skin window showed a ddaycd and diminished accumulation of balanced salt solution with Ca ++ , Mg+ +,and I '.:o gelatin (!lOSS- monocytcs (8), suggesting a possible defect in monocyte migra­ G). tion. Two recent studies on monocyte chemotaxis give conflict­ Actimtcd serum (AS) . Pooled normal human serum (PNHS) ing results. One, done in 1- to 5-day-old infants, reports de­ was stored in aliquots at -700 and thawed just before usc . The creased chemotaxis ( 15) and the other, done in cord blood, serum was activated with endotoxin (Esclzcriclzia coli 026:136, reports normal chemotaxis (16). Difco), 300 1-lg/ml at 37° for 60 min, followed by inactivation at The investigations reported here were designed to cvalualc 56° for 30 min. The proportions used were serum 0 . 1 ml, the cellular and humoral components of monocyte chemotaxis in endotoxin 0.1 ml, HBSS-G 1.0 ml, and MEM 0.8 ml, which the newborn infant, using cord blooLI . Previously, Miller (21) gave a final serum concentration of 5 %. This stimulus was tested had repo rted an impairment of neutrophil chemotaxis and in against both monocytcs and PMN's. the generation uf serum chemotactic factors in 3- to 5-day-old Appropriate controls, without any chemotactic stimuli, were infants. The present study was expanded to include neutrophil tested simultaneously . These consisted of 40% medium (RPM I chemotaxis (I) to sec whether the defects described in newborn for monocytcs and MEM for PMN's) and 60% HBSS-G. infants were also present in corLI blood, anLI (2) to sec whether the responses of monocytcs and ncutrophils resembled each CH EMOTAXIS ASSAY other. The test procedure was a modification of the method of Snyderman c/ at. (26). All assays were done in triplicate. MATERIALS AND METHODS Modified Boyden chemotactic chambers (Blind-Well, Nc uro­ Heparinized (20 units/ml) cord blood, obtained from healthy probc) were used. The wells of the chambers were filled with 0.2 full term infants, was tested within 4 hr of delivery. In every ml of the chemotactic stimulus, delivered with a calibrated pi- 677 678 PAIIWA ET AL. pette (Finnpipette, Neuroprobe). Numbered filters (Nude­ eight showed a decreased response and three had a response pore) of pore size 5 J.Lm for monocytes and 3 J.LII1 for PMN's were equal to that of adult PMN's (Table 2). The mean chemotactic placed over the filled wells, taking care not to trap bubbles. The response of cord PMN's was 79% of that of adults (P < 0.05) filter retainers were then screwed in, and the upper compart­ I3ackground counts of cord and adult PMN's wen; similar. ments charged with 0.2 ml of the appropriate cell suspension. The chambers were incubated at 3 7o in humidified air for a GENERATION OF SERUM CHEMOTACTIC FACTOR period of 90 min for monocytes and 45 min for PMN's. After incubation, the upper compartments were aspirated and the Cord sera generated less chemotactic activity for PMN's than filters were removed and stained in Mayer's hematoxylin. Cells did PNHS. The chemotactic response of adult PMN's to acti­ migrating to the undersurface of the filter were counted, using vated cord sera was 55% of that seen with activated PNHS, P < an ocular grid (7 x 7 mm), with a magnification of 1 ,000 times 0.0005 (Table 3). for monocytes and 400 times for PMN's. Ten random grid fields were counted on every filter. The results were expressed as the SERUM INIIIBITORS OF CIIEI\IOTAXIS mean number of cells per ocular grid and as a percentage of the Adult mononuclear cells suspended in serum showed a lower normal. monocyte chemotactic response than that of cells suspended in medium alone. PNHS was more inhibitory than cord serum, STUDY OF SERUM FACTORS there being 51% inhibition of monocyte chemotaxis by PNIIS, Using the basic techniques described above, experiments were and 26% inhibition by cord serum (Table 4). Monocytes in cord done to evaluate the following. serum showed a consistently higher response to I 0% AS than Ability to Generate Chemotactic Factor. Cord sera and PNHS when suspended in PNIIS (P < 0.05). On the other hand, the were tested simultaneously for chemotactic activity after endo­ response of PMN's suspended in cord serum varied from a toxin activation, using adult PMN's as test cells. slightly decreased to a slightly increased response as compared Inhibitors of Cells. Normal monocytes and PMN's were sus­ with cells suspended in PNHS, but no significant differences pened in either 10% cord serum or 10% PNIIS; 10% activated were observed. Only minimal inhibition by either serum was normal serum was used as the chemotactic stimulus. seen. Cord cells similarly suspended in either PNHS or cord Jnhibitors/lnactivators of Chemotactic Stimuli. Cord serum or serum were not tested. normal serum, 5%, was added to 5% activated normal serum. This 10% serum mixture was used as the chemotactic stimulus SERUM INHIBITORS/INACTIVATORS OF CHEMOTACTIC FACTORS for normal PMN's. Similarly, cord or normal serum, 10%, was There was no evidence of any inhibitor or inactivator in added to the 30% LDCF and tested against normal monocytes. unfractionated cord or pooled normal serum to either of the chemotactic factors tested. Monocytes exhibited an increased RESULTS response to LDCF which had added cord or pooled normal human serum than when exposed to LDCF alone (Table 5). MONOCYTE CHEMOTAXIS Addition of either 5% cord or pooled adult serum to 5% The percentage of monocytes in cord mononuclear cells was consistently higher than that in adult cells: 25 ± 8% versus 16 ± Table 2. Response of cord and adult polymorphonuclear 5%, respectively. The final monocyte concentrations were ad­ neutroplzils ( PMN's) to endotoxin-activated normal serum (AS) justed as described above such that the chambers all received equal numbers of either cord or adult monocytes. LDCF was the Mean chemotactic response' chemotactic stimulus for 24 cord samples; AS was used as an Cord/ additional stimulus in 12 (Table I).
Load more

Recommended publications
  • For Inflammatory Bowel Disease
    250 NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of leukapheresis (white cell apheresis) for inflammatory bowel disease Introduction This overview has been prepared to assist members of the Interventional Procedures Advisory Committee (IPAC) in making recommendations about the safety and efficacy of an interventional procedure. It is based on a rapid review of the medical literature and specialist opinion. It should not be regarded as a definitive assessment of the procedure. Date prepared This overview was prepared in August 2004. Procedure names • Leukapheresis • White cell apheresis. • Leukocyte removal therapy. • Selective granulocyte and monocyte adsorption apheresis. • Leukocytapheresis. Specialty society • British Society of Gastroenterology. Description Indications Inflammatory bowel disease. Ulcerative colitis and Crohn’s disease are the most common forms of inflammatory bowel disease. Ulcerative colitis causes inflammation and ulceration of the rectum and sometimes the colon. Symptoms include bloody diarrhoea and rectal bleeding. Crohn’s disease usually causes inflammation and ulceration of the small and large intestines, but it can affect any part of the digestive tract. The main symptoms are abdominal pain, diarrhoea and weight loss. Both of these are chronic conditions, characterised by periods of clinical relapse and remission. The incidence of ulcerative colitis is around 10 to 20 per 100,000 per year in the UK and the incidence of Crohn’s disease is approximately 5 to 10 per 100,000 per year.1 Current treatment and alternatives Conservative treatments include dietary measures, and medications to control inflammation. Immunosuppressants may be used if other medical therapies are ineffective at maintaining remission. Patients with ulcerative colitis that does not respond to medical therapy may be treated with surgery to remove the colon.
    [Show full text]
  • Adaptive Tdetect Fact Sheet for Recipient
    FACT SHEET FOR RECIPIENTS Coronavirus Adaptive Biotechnologies Corporation September 2, 2021 Disease 2019 T-Detect COVID Test (COVID-19) You are being given this Fact Sheet because your coughing, difficulty breathing, etc.). A full list of sample is being tested or was tested for an adaptive T- symptoms of COVID-19 can be found at the following cell immune response to the virus that causes link: https://www.cdc.gov/coronavirus/2019- Coronavirus Disease 2019 (COVID-19) using the T- ncov/symptoms-testing/symptoms.html. Detect COVID Test. How are people tested for COVID-19? Two main kinds of tests are currently available for You should not interpret the results of this COVID-19: diagnostic tests and adaptive immune response tests. test to indicate the presence or absence of immunity or protection from COVID-19 • A diagnostic test tells you if you have a current infection. infection. • An adaptive immune response test tells you if you may have had a previous infection This Fact Sheet contains information to help you understand the risks and benefits of using this test to What is the T-Detect COVID Test? evaluate your adaptive immune response to SARS-CoV- This test is similar to an antibody test in that it measures 2, the virus that causes COVID-19. After reading this your adaptive immune response to SARS-CoV-2, the Fact Sheet, if you have questions or would like to virus that causes COVID-19. However in this case it discuss the information provided, please talk to your specifically measures your adaptive T-cell immune healthcare provider.
    [Show full text]
  • Reference Ranges for Blood Concentrations of Eosinophils And
    Journal of Perinatology (2010) 30, 540–545 r 2010 Nature America, Inc. All rights reserved. 0743-8346/10 www.nature.com/jp ORIGINAL ARTICLE Reference ranges for blood concentrations of eosinophils and monocytes during the neonatal period defined from over 63 000 records in a multihospital health-care system RD Christensen1,2, J Jensen1,3, A Maheshwari4 and E Henry1,3 1Intermountain Healthcare Women and Newborns Clinical Program, Ogden, UT, USA; 2McKay-Dee Hospital Center, Ogden, UT, USA; 3Institute for Healthcare Delivery Research, Salt Lake City, UT, USA and 4Divisions of Neonatology and Pediatric Gastroenterology, Departments of Pediatrics, Cell Biology, and Pathology, University of Alabama at Birmingham, Birmingham, AL, USA Introduction Objective: Blood concentrations of eosinophils and monocytes are part Normal values for hematological parameters are not generally of the complete blood count. Reference ranges for these concentrations during available for neonates because blood is not drawn on healthy the neonatal period, established by very large sample sizes and modern neonates to establish normal ranges. Instead, ‘reference ranges’ are methods, are needed for identifying abnormally low or high values. used in neonatal hematology.1–6 These consist of the 5th to 95th Study Design: We constructed reference ranges for eosinophils per ml percentile values assembled from large numbers of neonates with and monocytes per ml among neonates of 22 to 42 weeks of gestation, minimal pathology or with pathology not thought to be relevant to on the day of birth, and also during 28 days after birth. Data were the laboratory parameter under study. Recent examples of their obtained from archived electronic records over an eight and one-half-year usefulness include the following: Reference ranges for erythrocyte period in a multihospital health-care system.
    [Show full text]
  • Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant
    Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children’s Research Hospital Departments of Hematology, Patient Education, and Biomedical Communications. Funds were provided by St. Jude Children’s Research Hospital, ALSAC, and a grant from the Plough Foundation. This document is not intended to take the place of the care and attention of your personal physician. Our goal is to promote active participation in your care and treatment by providing information and education. Questions about individual health concerns or specifi c treatment options should be discussed with your physician. For more general information on sickle cell disease, please visit our Web site at www.stjude.org/sicklecell. Copyright © 2009 St. Jude Children’s Research Hospital How did bone marrow (stem cell) transplants begin for children with sickle cell disease? Bone marrow (stem cell) transplants have been used for the treatment and cure of a variety of cancers, immune system diseases, and blood diseases for many years. Doctors in the United States and other countries have developed studies to treat children who have severe sickle cell disease with bone marrow (stem cell) transplants. How does a bone marrow (stem cell) transplant work? 2 In a person with sickle cell disease, the bone marrow produces red blood cells that contain hemoglobin S. This leads to the complications of sickle cell disease. • To prepare for a bone marrow (stem cell) transplant, strong medicines, called chemotherapy, are used to weaken or destroy the patient’s own bone marrow, stem cells, and infection fi ghting system.
    [Show full text]
  • Adaptive Immune Systems
    Immunology 101 (for the Non-Immunologist) Abhinav Deol, MD Assistant Professor of Oncology Wayne State University/ Karmanos Cancer Institute, Detroit MI Presentation originally prepared and presented by Stephen Shiao MD, PhD Department of Radiation Oncology Cedars-Sinai Medical Center Disclosures Bristol-Myers Squibb – Contracted Research What is the immune system? A network of proteins, cells, tissues and organs all coordinated for one purpose: to defend one organism from another It is an infinitely adaptable system to combat the complex and endless variety of pathogens it must address Outline Structure of the immune system Anatomy of an immune response Role of the immune system in disease: infection, cancer and autoimmunity Organs of the Immune System Major organs of the immune system 1. Bone marrow – production of immune cells 2. Thymus – education of immune cells 3. Lymph Nodes – where an immune response is produced 4. Spleen – dual role for immune responses (especially antibody production) and cell recycling Origins of the Immune System B-Cell B-Cell Self-Renewing Common Progenitor Natural Killer Lymphoid Cell Progenitor Thymic T-Cell Selection Hematopoetic T-Cell Stem Cell Progenitor Dendritic Cell Myeloid Progenitor Granulocyte/M Macrophage onocyte Progenitor The Immune Response: The Art of War “Know your enemy and know yourself and you can fight a hundred battles without disaster.” -Sun Tzu, The Art of War Immunity: Two Systems and Their Key Players Adaptive Immunity Innate Immunity Dendritic cells (DC) B cells Phagocytes (Macrophages, Neutrophils) Natural Killer (NK) Cells T cells Dendritic Cells: “Commanders-in-Chief” • Function: Serve as the gateway between the innate and adaptive immune systems.
    [Show full text]
  • Generation of Monocyte-Derived Tumor-Associated Macrophages Using
    Benner et al. Journal for ImmunoTherapy of Cancer (2019) 7:140 J Immunother Cancer: first published as 10.1186/s40425-019-0622-0 on 28 May 2019. Downloaded from https://doi.org/10.1186/s40425-019-0622-0 RESEARCHARTICLE Open Access Generation of monocyte-derived tumor- associated macrophages using tumor- conditioned media provides a novel method to study tumor-associated macrophages in vitro Brooke Benner1, Luke Scarberry1, Lorena P. Suarez-Kelly2, Megan C. Duggan1, Amanda R. Campbell1, Emily Smith1, Gabriella Lapurga1, Kallie Jiang1, Jonathan P. Butchar1, Susheela Tridandapani1, John Harrison Howard2, Robert A. Baiocchi3, Thomas A. Mace1 and William E. Carson III1,2* Abstract Background: Tumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do not include exogenous growth factors from the tumor, a key factor in TAM differentiation in vivo. Methods: In this study, an in vitro method to generate monocyte- derived TAM using tumor- conditioned media (TCM) and a cytokine cocktail containing IL-4, IL-10, and M-CSF was utilized to study the phenotype, morphology, and function of TAM across multiple cancer types. TCM was generated from two breast cancer cell lines and an Epstein-Barr virus-positive lymphoma cell line. The properties of in vitro generated TAM were compared to in vitro generated M1 and M2- like macrophages and TAM isolated from patients with cancer. Results: TAM generated in this fashion displayed an increase in CD163/CD206 co-expression compared to M2- like http://jitc.bmj.com/ macrophages (87 and 36%, respectively).
    [Show full text]
  • Myelodysplastic Syndromes Overview and Types
    cancer.org | 1.800.227.2345 About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Myelodysplastic Syndromes? ● Types of Myelodysplastic Syndromes Research and Statistics See the latest estimates for new cases of myelodysplastic syndromes in the US and what research is currently being done. ● Key Statistics for Myelodysplastic Syndromes ● What's New in Myelodysplastic Syndrome Research? What Are Myelodysplastic Syndromes? Myelodysplastic syndromes (MDS) are conditions that can occur when the blood- forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells. MDS is considered a type of cancer1. Normal bone marrow 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Bone marrow is found in the middle of certain bones. It is made up of blood-forming cells, fat cells, and supporting tissues. A small fraction of the blood-forming cells are blood stem cells. Stem cells are needed to make new blood cells. There are 3 main types of blood cells: red blood cells, white blood cells, and platelets. Red blood cells pick up oxygen in the lungs and carry it to the rest of the body. These cells also bring carbon dioxide back to the lungs. Having too few red blood cells is called anemia. It can make a person feel tired and weak and look pale. Severe anemia can cause shortness of breath. White blood cells (also known as leukocytes) are important in defending the body against infection.
    [Show full text]
  • Immune Effector Monocyte–Neutrophil Cooperation Induced by the Primary Tumor Prevents Metastatic Progression of Breast Cancer
    Immune effector monocyte–neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer Catharina Hagerlinga,b,1,2, Hugo Gonzaleza,3, Kiarash Salaria,3, Chih-Yang Wanga,4, Charlene Lina, Isabella Roblesa, Merel van Gogha, Annika Dejmekc, Karin Jirströmb, and Zena Werba,d,2 aDepartment of Anatomy, University of California, San Francisco, CA 94143-0452; bDepartment of Clinical Sciences, Division of Clinical Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden; cDepartment of Translational Medicine, Lund University, Malmö SUS, SE-214 21 Malmö, Sweden; and dHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143 Contributed by Zena Werb, August 30, 2019 (sent for review May 3, 2019; reviewed by Yves DeClerck and Mikala Egeblad) Metastatic behavior varies significantly among breast cancers. Mech- patients’ breast cancer tumors and is hence an attractive preclinical anisms explaining why the majorityofbreastcancerpatientsnever model to find novel therapeutic alternatives for metastatic breast develop metastatic outgrowth are largely lacking but could underlie cancer (12). We furthermore validated our PDX-derived findings the development of novel immunotherapeutic target molecules. Here with a large primary breast cancer tissue microarray (TMA), pleural we show interplay between nonmetastatic primary breast cancer effusions from breast cancer patients and an immunocompetent and innate immune response, acting together to control metastatic syngeneic mammary cancer model. Taken together, we reveal in- progression. The primary tumor systemically recruits IFNγ-producing terplay between the primary breast cancer tumor and myeloid im- immune effector monocytes to the lung. IFNγ up-regulates Tmem173/ mune response, acting together to control metastatic progression.
    [Show full text]
  • Stress and the Immune System Tracy B
    4 World Health • 47th Yeor, No. 2, Morch-Aprill994 Stress and the immune system Tracy B. Herbert any people have the effects of factors as diverse as experienced the examinations, bereavement, divorce, Mconnection between stress unemployment, mental arithmetic, and getting sick. Colds, influenza, and looking after a relative with herpes and allergies seem worse Alzheimer's di sease. In general, when we are severely stressed at these studies find that stress is work or in the home. Others are related to changes in both the never sick until they go on vacation numbers of white blood cells in (that is, after the stress is over), and circulation and the quantity of then they spend the whole time antibody in the blood. Moreover, fighting the virus. Because of stress is associated with changes in intrinsic connections like these, the functioning of immune cells. many researchers are today That is, there is a relatively large exploring whether (and how) stress decrease in both lymphocyte and illness are actually linked. One proliferation and natural killer cell specific focus of this research is to activity in individuals who have study the effects of stress on the experienced stress. There seems to immune systems; after all, if stress A lymphocyte: stress may weaken the capacity be some connection between the affects immunity, that would be one of lymphocytes to combat infection. duration of the stress and the amount way in which stress could contribute of immune change. For example, the to illness. longer the stress, the greater the The function of the immune proliferation"- by incubating these decrease in the number of specific system is to protect us from cells for several days with types of white blood cells.
    [Show full text]
  • LECTURE 05 Acquired Immunity and Clonal Selection
    LECTURE: 05 Title: ACQUIRED "ADAPTIVE" IMMUNITY & CLONAL SELECTION THEROY LEARNING OBJECTIVES: The student should be able to: • Recognize that, acquired or adaptive immunity is a specific immunity. • Explain the mechanism of development of the specific immunity. • Enumerate the components of the specific immunity such as A. Primary immune response. B. Secondary immune response • Explain the different phases that are included in the primary and secondary immune responses such as: A. The induction phase. B. Exponential phase. C. Steady phase. D. Decline phase. • Compare between the phases of the primary and secondary immune responses. • Determine the type of the immunoglobulins involved in each phase. • Determine which immunoglobulin is induced first and, that last longer. • Enumerate the characteristics of the specific immunity such as: A. The ability to distinguish self from non-self. B. Specificity. C. Immunological memory. • Explain naturally and artificially acquired immunity (passive, and active). • Explain the two interrelated and independent mechanisms of the specific immune response such as : A. Humoral immunity. B. Cell-mediated (cellular) immunity. • Recognize that, the specific immunity is not always protective, for example; sometimes it causes allergies (hay fever), or it may be directed against one of the body’s own constituents, resulting in autoimmunity (thyroditis). LECTURE REFRENCE: 1. TEXTBOOK: ROITT, BROSTOFF, MALE IMMUNOLOGY. 6th edition. Chapter 2. pp. 15-31 2. TEXTBOOK: ABUL K. ABBAS. ANDREW H. LICHTMAN. CELLULAR AND MOLECULAR IMMUNOLOGY. 5TH EDITION. Chapter 1. pg 3-12. 1 ACQUIRED (SPECIFIC) IMMUNITY INTRODUCTION Adaptive immunity is created after an interaction of lymphocytes with particular foreign substances which are recognized specifically by those lymphocytes.
    [Show full text]
  • Your Blood Cells
    Page 1 of 2 Original Date The Johns Hopkins Hospital Patient Information 12/00 Oncology ReviseD/ RevieweD 6/14 Your Blood Cells Where are Blood cells are made in the bone marrow. The bone marrow blood cells is a liquid that looks like blood. It is found in several places of made? the body, such as your hips, chest bone and the middle part of your arm and leg bones. What types of • The three main types of blood cells are the red blood cells, blood cells do the white blood cells and the platelets. I have? • Red blood cells carry oxygen to all parts of the body. The normal hematocrit (or percentage of red blood cells in the blood) is 41-53%. Anemia means low red blood cells. • White blood cells fight infection. The normal white blood cell count is 4.5-11 (K/cu mm). The most important white blood cell to fight infection is the neutrophil. Forty to seventy percent (40-70%) of your white blood cells should be neutrophils. Neutropenia means your neutrophils are low, or less than 40%. • Platelets help your blood to clot and stop bleeding. The normal platelet count is 150-350 (K/cu mm). Thrombocytopenia means low platelets. How do you Your blood cells are measured by a test called the Complete measure my Blood Count (CBC) or Heme 8/Diff. You may want to keep track blood cells? of your blood counts on the back of this sheet. What When your blood counts are low, you may become anemic, get happens infections and bleed or bruise easier.
    [Show full text]
  • Rapid Induction of Antigen-Specific CD4+ T Cells Guides Coordinated Humoral and Cellular Immune Responses to SARS-Cov-2 Mrna Vaccination
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440862; this version posted April 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination Authors: Mark M. Painter1,2, †, Divij Mathew1,2, †, Rishi R. Goel1,2, †, Sokratis A. Apostolidis1,2,3, †, Ajinkya Pattekar2, Oliva Kuthuru1, Amy E. Baxter1, Ramin S. Herati4, Derek A. Oldridge1,5, Sigrid Gouma6, Philip Hicks6, Sarah Dysinger6, Kendall A. Lundgreen6, Leticia Kuri-Cervantes1,6, Sharon Adamski2, Amanda Hicks2, Scott Korte2, Josephine R. Giles1,7,8, Madison E. Weirick6, Christopher M. McAllister6, Jeanette Dougherty1, Sherea Long1, Kurt D’Andrea1, Jacob T. Hamilton2,6, Michael R. Betts1,6, Paul Bates6, Scott E. Hensley6, Alba Grifoni9, Daniela Weiskopf9, Alessandro Sette9, Allison R. Greenplate1,2, E. John Wherry1,2,7,8,* Affiliations 1 Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 2 Immune Health™, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 3 Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 4 NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY 5 Department
    [Show full text]